Our Lead Drug Quizartinib

An once-a-day, orally administered, potent and selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML).

Learn About Quizartinib» View Recent Presentations»

A Kinase Targeted Pipeline

We leverage our kinase expertise to discover, optimize and develop a sustainable pipeline of small molecule kinase inhibitors.

Learn About Our Pipeline»